Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.
Article CAS PubMed Google Scholar
Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2021;84(1):46–52.
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6.
Liu J, Thatiparthi A, Martin A, Egeberg A, Wu JJ. Prevalence of psoriasis among adults in the US 2009–2010 and 2013–2014 National Health and Nutrition Examination Surveys. J Am Acad Dermatol. 2021;84(3):767–9.
Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863–72.
Article CAS PubMed Google Scholar
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.
Article PubMed PubMed Central Google Scholar
Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–9.
Article PubMed PubMed Central Google Scholar
Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287-92.e4.
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54-e.
Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–11.
Article CAS PubMed Google Scholar
Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917–25.
Article CAS PubMed PubMed Central Google Scholar
Assan F, Tubach F, Arlegui H, et al. First-line biologic therapy and obesity in moderate-to-severe psoriasis: results from the prospective multicenter cohort PSOBIOTEQ. Dermatology. 2021;237(3):338–46.
Article CAS PubMed Google Scholar
Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76.
Article CAS PubMed Google Scholar
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
FDA [Internet]. Food and Drug Administration. TREMFYA (guselkumab) Injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf. Accessed 20 Mar 2022.
Armstrong AW, Fitzgerald T, McLean RR, et al. Effectiveness of guselkumab therapy among patients with plaque psoriasis with baseline IGA score ≥ 2 in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022;13:487–504.
Article PubMed PubMed Central Google Scholar
Armstrong AW, Fitzgerald T, McLean RR, et al. Real-world effectiveness of 9–12 months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022;13:629–40.
Article PubMed PubMed Central Google Scholar
Chan Y, Tong BSB, Ngan PY, Au CS. Effectiveness of IL-23 inhibitor guselkumab in real-world Chinese patients with psoriasis during a 20-week period. Psoriasis (Auckl). 2021;11:53–8.
del Alcázar E, López-Ferrer A, Martínez-Doménech Á, et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(2): e15231.
Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.
Article CAS PubMed PubMed Central Google Scholar
Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–62.
Article CAS PubMed Google Scholar
Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205–12.
Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–4.
Article CAS PubMed Google Scholar
Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6): e13964.
Article CAS PubMed Google Scholar
Zhuang J-Y, Li J-S, Zhong Y-Q, et al. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population. Dermatol Ther. 2021;34(5): e15054.
Article CAS PubMed Google Scholar
Gordon KB, Blauvelt A, Foley P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178(1):132–9.
Article CAS PubMed Google Scholar
Blauvelt A, Armstrong AW, Langley RG et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatolog Treat. 2022;33(4):2317–24.
Article CAS PubMed Google Scholar
Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810–23.
Article PubMed PubMed Central Google Scholar
Williamson K, Nimegeer A, Lean M. Rising prevalence of BMI ≥40 kg/m^2: a high-demand epidemic needing better documentation. Obes Rev. 2020;21(4): e12986.
Article PubMed PubMed Central Google Scholar
World Health Organization. Noncommunicable diseases country profiles 2018. 2018.
Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–32.
Strober BE, Germino R, Guana A, et al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatolog Treat. 2020;31(4):333–41.
Article CAS PubMed Google Scholar
Walsh JA, Callis Duffin K, Van Voorhees AS, et al. Demographics, disease characteristics, and patient-reported outcomes among patients with psoriasis who initiated guselkumab in CorEvitas’ Psoriasis Registry. Dermatol Ther (Heidelb). 2022;12(1):97–119.
Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–6.
EuroQoL Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
Article CAS PubMed Google Scholar
Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.
Article CAS PubMed Google Scholar
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.
Article CAS PubMed Google Scholar
Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4): e027535.
留言 (0)